MBX Biosciences (MBX) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MBX Biosciences (MBX) has outperformed Trevi Therapeutics (TRVI) over the past year, gaining 235.8% versus a gain of 30.6%. MBX Biosciences is the larger company by market cap ($2.54 billion vs $1.86 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | TRVI |
|---|---|---|
| Share price | $52.75 | $13.02 |
| Market cap | $2.54B | $1.86B |
| 1-day change | -0.94% | +1.52% |
| YTD return | +68.83% | +2.44% |
| 1-year return | +235.75% | +30.60% |
| 5-year return | — | +894.19% |
| EPS (TTM) | $-2.37 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-87.00M | $-42.76M |
| 52-week high | $72.64 | $20.22 |
| 52-week low | $12.94 | $9.28 |
| Distance from 52-week high | -27.38% | -35.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +78.77% | +116.44% |
| Average volume | 534.13K | 2.03M |
| Shares outstanding | 48.16M | 142.48M |
| Employees | 63 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed TRVI by 205.1 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
MBX vs TRVI FAQ
Which is bigger, MBX Biosciences or Trevi Therapeutics?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.54B compared with $1.86B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, MBX or TRVI?
MBX returned +235.75% over the past 12 months, compared with +30.60% for TRVI (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.